Reporter brief
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
What happened
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- This is a protocol proposal, not a completed study with results; no efficacy or safety data are reported. The study hypothesizes benefit based on prior work in normal kidney function and animal models, but translation to moderate-to-severe CKD remains untested. Sample size, power calculation, and primary outcome effect estimates are not provided, making it impossible to assess whether the proposed design is adequate.
Study design and sample
Rct; Human.
Patients with stage III and IV chronic kidney disease (CKD), ages 35-80 years
- Design
- Rct
- Sample
- —
- Journal
- University of Colorado, Denver
- Published
- Oct 2, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Nicotinamide riboside timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.